|
|
|
|
|
14.07.25 - 15:54
|
Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board (Business Wire)
|
|
|
MADISON, Wis.--(BUSINESS WIRE)--Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its Scientific Advisory Board (SAB). Dr. Korman brings a wealth of experience in immuno-oncology, having played a pivotal role in the development of groundbreaking cancer immunotherapies.
Dr. Korman is currently CSO and a member of the Board of Directors of Bluesphere Bio, a clinical stage biotech company in Pittsburgh, PA. Most recently, he served as Senior Vice President of Human Immunology at Vir Biotechnology. Prior to that, he served as Vice President for Immuno-Oncology Discovery at Bristol-Myers Squibb (BMS), where he led the development of biologics for tumor immunotherapy. During his tenure at BMS and Medarex, Dr. Korman contributed to the development of three approved oncology drugs: ipilimumab (anti-CTLA-4), nivolumab (anti-PD-1), and relatlimab (anti-LAG-3), as well as their...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.07.25 - 23:45
|
XETR: DIVIDEND/INTEREST INFORMATION - 03.07.2025 - BRM (XETRA)
|
|
|
Das Instrument BRM US1101221083 BRISTOL-MYERS SQUIBBDL-10 EQUITY wird cum Dividende/Zinsen gehandelt am 02.07.2025 und ex Dividende/Zinsen am 03.07.2025
The instrument BRM US1101221083 BRISTOL-MYERS SQUIBBDL-10 EQUITY has its pre-dividend/interest day on 02.07.2025 and its ex-dividend/interest day on 03.07.2025...
|
|
|
|
|
01.07.25 - 14:03
|
Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer (Business Wire)
|
|
|
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the appointment of Shishir Gadam, Ph.D., as chief technical officer. Dr. Gadam has extensive experience in the biotechnology industry and brings deep expertise and leadership in biologics development and manufacturing to Marea Therapeutics.
Dr. Gadam was most recently chief technical officer at Cargo Therapeutics and responsible for technical operations for the cell therapy portfolio. Prior to Cargo, he held the position of vice president and head of cell therapy global manufacturing sciences & technology at Juno therapeutics, a Celgene company and Bristol Myers Squibb where he was instrumental in launch of two cell therapy commercial CAR-T products. During his tenure at Genetech/Roche from 2006-2018, he held positions of increasing responsibility acr...
|
|
|
|
|
|
|
26.06.25 - 19:00
|
This Once Dominant Dividend Stock May Be About to Come Back to Life in July (24/7 Wall St.)
|
|
|
For income investors seeking a timely value stock to buy on the dip, former dividend darling Bristol-Myers Squibb (NYSE:BMY) may fit the bill as one of the top names to watch in the month of July. Undoubtedly, the stock has been under harsh pressure since peaking in the back half of 2022, now down more […]
The post This Once Dominant Dividend Stock May Be About to Come Back to Life in July appeared first on 24/7 Wall St.....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
